Baseline and on-treatment peripheral blood cytokines are associated with immune-related adverse events during PD-1 inhibitor therapy: development and internal assessment of a nomogram and machine-learning models
Year: 2026
Type: article
Study design: Observational Study
Abstract: Objective Immune-related adverse events (irAEs) are a major limitation of PD-1 inhibitor therapy, and clinically actionable biomarkers for early risk stratification remain limited. We investigated whether baseline and early dynamic changes in peripheral blood cytokines could predict irAEs and severe irAEs. Methods We retrospectively enrolled patients initiating PD-1 inhibitor therapy at two centers (January 2021–December 2023). Plasma levels of 12 cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17, IFN-α, IFN-γ, TNF-α) were measured within 7 days before each cycle. For predicting any irAE, we developed a nomogram using feature selection (univariate logistic regression, Bayesian stepwise regression, and LASSO) followed by multivariable logistic regression. For predicting severe irAEs (grade ≥3), we evaluated cytokine change rates (Δ) at Cycle 2 and constructed machine-learning classifiers (KNN, SVM, regression tree, random forest, and XGBoost) with cross-validation. Results Among 210 patients, 151 (71.9%) developed irAEs and 41 (19.5%) experienced grade ≥3 irAEs. To predict the occurrence of any irAE (yes/no) in the overall cohort, the LASSO-selected nomogram demonstrated good discrimination in the validation set (AUC = 0.853), with favorable calibration and decision-curve performance. In the irAE subgroup, cytokine change rates (Δ, baseline to Cycle 2) peaked at Cycle 2, and Δ cytokine–based machine-learning classifiers showed promising performance for distinguishing severe (grade ≥3) from mild (grade 1–2) irAEs in the validation set (SVM with polynomial kernel AUC = 0.944; XGBoost AUC = 0.909). Conclusion Baseline cytokines combined with early dynamic cytokine changes may support exploratory risk stratification for irAEs. Larger prospective cohorts and external validation are required before clinical implementation.
Source: Frontiers in Immunology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7226023072
